Peripheral Vascular Stent MarketThe global peripheral vascular stent market is poised for significant expansion, with an expected market value of USD 4,267.70 million in 2024. As the demand for ...

Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up ...

Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the ...

National health insurance coverage extended for arterial thrombectomy procedures within 24 hours | Feb. 19, 2025 11:35 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...

Welireg is intended for adults with VHL disease who need therapy for associated renal cell carcinoma (RCC), central nervous ...

Q4 2024 Earnings Call Transcript February 18, 2025 Penumbra, Inc. beats earnings expectations. Reported EPS is $0.97, expectations were $0.88. Operator: Good afternoon. My name is Rob and I will be ...

US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received conditional approval from the European ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...

A reliable method to treat post-amputation pain remains elusive, but a new Northwestern Medicine study conducted in ...